MA52488B1 - Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation - Google Patents
Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisationInfo
- Publication number
- MA52488B1 MA52488B1 MA52488A MA52488A MA52488B1 MA 52488 B1 MA52488 B1 MA 52488B1 MA 52488 A MA52488 A MA 52488A MA 52488 A MA52488 A MA 52488A MA 52488 B1 MA52488 B1 MA 52488B1
- Authority
- MA
- Morocco
- Prior art keywords
- rip1
- making
- methods
- inhibitory compounds
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102100021009 Cytochrome b-c1 complex subunit Rieske, mitochondrial Human genes 0.000 title 1
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 title 1
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 title 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102100021559 KRR1 small subunit processome component homolog Human genes 0.000 abstract 2
- 101150040948 RIP1 gene Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 1
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
L'invention concerne des composés inhibiteurs de kinase, tels qu'un composé inhibiteur de la protéine-1 interagissant avec le récepteur (rip1), ainsi que des compositions pharmaceutiques et des combinaisons comprenant de tels composés inhibiteurs. Les composés décrits, les compositions pharmaceutiques et/ou les combinaisons peuvent être utilisés pour traiter ou prévenir une maladie ou un état associé à une kinase, en particulier une maladie ou un état associé à rip1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666462P | 2018-05-03 | 2018-05-03 | |
| PCT/US2019/030476 WO2019213447A1 (fr) | 2018-05-03 | 2019-05-02 | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA52488A MA52488A (fr) | 2021-03-10 |
| MA52488B1 true MA52488B1 (fr) | 2023-11-30 |
Family
ID=66530556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA52488A MA52488B1 (fr) | 2018-05-03 | 2019-05-02 | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation |
Country Status (36)
| Country | Link |
|---|---|
| US (7) | US10815206B2 (fr) |
| EP (2) | EP4248975A3 (fr) |
| JP (4) | JP2021523226A (fr) |
| KR (1) | KR20210005222A (fr) |
| CN (1) | CN112368278A (fr) |
| AU (2) | AU2019262144B2 (fr) |
| BR (1) | BR112020022420A2 (fr) |
| CA (1) | CA3099037A1 (fr) |
| CL (1) | CL2020002841A1 (fr) |
| CO (1) | CO2020015156A2 (fr) |
| CR (1) | CR20200581A (fr) |
| DK (1) | DK3788044T3 (fr) |
| DO (2) | DOP2020000198A (fr) |
| EA (1) | EA202092580A1 (fr) |
| EC (1) | ECSP20078326A (fr) |
| ES (1) | ES2956087T3 (fr) |
| FI (1) | FI3788044T3 (fr) |
| HR (1) | HRP20231381T1 (fr) |
| HU (1) | HUE063896T2 (fr) |
| IL (2) | IL278417B2 (fr) |
| JO (1) | JOP20200278A1 (fr) |
| LT (1) | LT3788044T (fr) |
| MA (1) | MA52488B1 (fr) |
| MD (1) | MD3788044T2 (fr) |
| MX (1) | MX2020011621A (fr) |
| PE (1) | PE20211383A1 (fr) |
| PH (1) | PH12020551847A1 (fr) |
| PL (1) | PL3788044T3 (fr) |
| PT (1) | PT3788044T (fr) |
| RS (1) | RS64736B1 (fr) |
| SA (1) | SA520420468B1 (fr) |
| SG (1) | SG11202010915XA (fr) |
| SI (1) | SI3788044T1 (fr) |
| UA (1) | UA128369C2 (fr) |
| WO (1) | WO2019213447A1 (fr) |
| ZA (2) | ZA202007486B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3788045T1 (sl) | 2018-05-03 | 2023-07-31 | Rigel Pharmaceuticals, Inc. | Zaviralne spojine RIP1 in postopki njihove izdelave in uporabe |
| CA3099037A1 (fr) | 2018-05-03 | 2019-11-07 | Rigel Pharmaceuticals, Inc. | Composes inhibiteurs de rip1 et leurs procedes de fabrication et d'utilisation |
| CN111138448B (zh) * | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| WO2020088194A1 (fr) * | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | Amide hétérocyclique inhibant la kinase rip1 et ses applications |
| US20210040115A1 (en) * | 2019-08-09 | 2021-02-11 | Bisichem Co., Ltd. | Fused ring heteroaryl compounds as ripk1 inhibitors |
| US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
| AU2020341681B2 (en) * | 2019-09-06 | 2024-02-15 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| JOP20220056A1 (ar) * | 2019-09-06 | 2023-01-30 | Rigel Pharmaceuticals Inc | مركبات rip1 تثبيطية وطرق عملها واستخدامها |
| AU2020353663A1 (en) | 2019-09-27 | 2022-04-07 | Board Of Regents, The University Of Texas System | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease |
| EP3861676A1 (fr) * | 2019-10-21 | 2021-08-11 | Google LLC | Consentement vérifiable permettant la protection de la vie privée |
| CN115298184A (zh) | 2019-11-07 | 2022-11-04 | 里格尔药品股份有限公司 | 杂环rip1抑制化合物 |
| JP2023502514A (ja) * | 2019-11-26 | 2023-01-24 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
| JP2023515971A (ja) * | 2020-02-28 | 2023-04-17 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI824259B (zh) | 2020-07-01 | 2023-12-01 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| WO2022171111A1 (fr) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Composé bicyclique fusionné hétéroaryle utile en tant qu'inhibiteur de la rip1-kinase et ses utilisations |
| CN114989156B (zh) * | 2021-05-19 | 2024-07-05 | 成都贝诺科成生物科技有限公司 | 一种受体相互作用蛋白抑制剂及其制备方法和用途 |
| AR126733A1 (es) | 2021-08-10 | 2023-11-08 | Abbvie Inc | Inhibidores de nicotinamida ripk1 |
| CA3240557A1 (fr) | 2021-12-16 | 2023-06-22 | Shaoming DUAN | Formes cristallines d'un inhibiteur de ripk1 |
| WO2023138317A1 (fr) * | 2022-01-21 | 2023-07-27 | 中国科学院上海药物研究所 | Composé ayant une activité inhibitrice de ripk1, son procédé de préparation et son utilisation |
| CN114736197B (zh) * | 2022-06-13 | 2022-09-13 | 南京医工医药技术有限公司 | 咪唑啉酮衍生物及其用途 |
| CN115353513A (zh) * | 2022-07-29 | 2022-11-18 | 中国人民解放军海军军医大学 | 一种抑制程序性细胞坏死的硫代七元环衍生物及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| PT96059B (pt) | 1989-12-04 | 1998-07-31 | Searle & Co | Sistema de camada unica para a administracao de um medicamento por via transdermica |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| EP0617665B1 (fr) | 1991-12-18 | 1999-03-31 | Minnesota Mining And Manufacturing Company | Structures d'arret stratifiees |
| EP0553769B1 (fr) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Raquette, en particulier raquette de tennis |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| US20090099242A1 (en) | 2007-08-15 | 2009-04-16 | Cuny Gregory D | Heterocyclic inhibitors of necroptosis |
| TWI648273B (zh) * | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類（三） |
| US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
| JP2017524028A (ja) * | 2014-08-21 | 2017-08-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 薬剤としてのｒｉｐ１キナーゼ阻害剤である複素環式アミド |
| BR112017017411A2 (pt) | 2015-02-13 | 2018-04-03 | Glaxosmithkline Ip Dev Ltd | Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida |
| EP3760625B1 (fr) * | 2015-07-02 | 2024-03-27 | F. Hoffmann-La Roche AG | Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 (rip1) interagissant avec des récepteurs pour le traitment par ex. de maladies inflammatoires |
| EP3362449B1 (fr) | 2015-10-13 | 2021-06-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Dérivés de sibiriline destinés à être utilisés pour prévenir et/ou traiter des troubles associés à la nécroptose cellulaire |
| US10787462B2 (en) | 2015-10-23 | 2020-09-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2017109724A1 (fr) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase |
| TN2018000276A1 (en) * | 2016-02-05 | 2020-01-16 | Denali Therapeutics Inc | Inhibitors of receptor-interacting protein kinase 1. |
| CN109843886B (zh) * | 2016-10-17 | 2022-04-19 | 豪夫迈·罗氏有限公司 | 二环吡啶酮内酰胺及其使用方法 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US20200062735A1 (en) * | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CA3099037A1 (fr) * | 2018-05-03 | 2019-11-07 | Rigel Pharmaceuticals, Inc. | Composes inhibiteurs de rip1 et leurs procedes de fabrication et d'utilisation |
| SI3788045T1 (sl) * | 2018-05-03 | 2023-07-31 | Rigel Pharmaceuticals, Inc. | Zaviralne spojine RIP1 in postopki njihove izdelave in uporabe |
| CA3104757A1 (fr) | 2018-06-26 | 2020-01-02 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Inhibiteur de necrose cellulaire, son procede de preparation et son utilisation |
| WO2020088194A1 (fr) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | Amide hétérocyclique inhibant la kinase rip1 et ses applications |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| AU2020341681B2 (en) | 2019-09-06 | 2024-02-15 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
-
2019
- 2019-05-02 CA CA3099037A patent/CA3099037A1/fr active Pending
- 2019-05-02 MA MA52488A patent/MA52488B1/fr unknown
- 2019-05-02 BR BR112020022420-0A patent/BR112020022420A2/pt active Search and Examination
- 2019-05-02 HU HUE19724048A patent/HUE063896T2/hu unknown
- 2019-05-02 JP JP2021510284A patent/JP2021523226A/ja not_active Withdrawn
- 2019-05-02 SI SI201930598T patent/SI3788044T1/sl unknown
- 2019-05-02 CR CR20200581A patent/CR20200581A/es unknown
- 2019-05-02 EP EP23181764.4A patent/EP4248975A3/fr active Pending
- 2019-05-02 LT LTEPPCT/US2019/030476T patent/LT3788044T/lt unknown
- 2019-05-02 ES ES19724048T patent/ES2956087T3/es active Active
- 2019-05-02 CN CN201980045101.1A patent/CN112368278A/zh active Pending
- 2019-05-02 UA UAA202007531A patent/UA128369C2/uk unknown
- 2019-05-02 AU AU2019262144A patent/AU2019262144B2/en active Active
- 2019-05-02 WO PCT/US2019/030476 patent/WO2019213447A1/fr active Application Filing
- 2019-05-02 MD MDE20210212T patent/MD3788044T2/ro unknown
- 2019-05-02 MX MX2020011621A patent/MX2020011621A/es unknown
- 2019-05-02 JO JOP/2020/0278A patent/JOP20200278A1/ar unknown
- 2019-05-02 PE PE2020001784A patent/PE20211383A1/es unknown
- 2019-05-02 HR HRP20231381TT patent/HRP20231381T1/hr unknown
- 2019-05-02 IL IL278417A patent/IL278417B2/en unknown
- 2019-05-02 KR KR1020207034549A patent/KR20210005222A/ko unknown
- 2019-05-02 RS RS20230982A patent/RS64736B1/sr unknown
- 2019-05-02 IL IL299784A patent/IL299784B2/en unknown
- 2019-05-02 US US16/402,111 patent/US10815206B2/en active Active
- 2019-05-02 PT PT197240484T patent/PT3788044T/pt unknown
- 2019-05-02 EP EP19724048.4A patent/EP3788044B1/fr active Active
- 2019-05-02 SG SG11202010915XA patent/SG11202010915XA/en unknown
- 2019-05-02 FI FIEP19724048.4T patent/FI3788044T3/fi active
- 2019-05-02 EA EA202092580A patent/EA202092580A1/ru unknown
- 2019-05-02 PL PL19724048.4T patent/PL3788044T3/pl unknown
- 2019-05-02 DK DK19724048.4T patent/DK3788044T3/da active
-
2020
- 2020-09-16 US US17/023,127 patent/US11332451B2/en active Active
- 2020-09-16 US US17/023,136 patent/US11370764B2/en active Active
- 2020-09-16 US US17/023,138 patent/US11377428B2/en active Active
- 2020-09-16 US US17/023,149 patent/US11370765B2/en active Active
- 2020-10-16 US US17/072,862 patent/US11472782B2/en active Active
- 2020-11-02 CL CL2020002841A patent/CL2020002841A1/es unknown
- 2020-11-02 DO DO2020000198A patent/DOP2020000198A/es unknown
- 2020-11-03 PH PH12020551847A patent/PH12020551847A1/en unknown
- 2020-11-03 SA SA520420468A patent/SA520420468B1/ar unknown
- 2020-12-01 CO CONC2020/0015156A patent/CO2020015156A2/es unknown
- 2020-12-01 ZA ZA2020/07486A patent/ZA202007486B/en unknown
- 2020-12-03 EC ECSENADI202078326A patent/ECSP20078326A/es unknown
-
2021
- 2021-11-04 ZA ZA2021/08603A patent/ZA202108603B/en unknown
-
2022
- 2022-08-10 JP JP2022128202A patent/JP7187729B2/ja active Active
- 2022-09-07 US US17/939,020 patent/US20230113841A1/en active Pending
- 2022-11-30 JP JP2022191875A patent/JP7367169B2/ja active Active
-
2023
- 2023-08-25 DO DO2023000169A patent/DOP2023000169A/es unknown
- 2023-10-11 JP JP2023175695A patent/JP2024009916A/ja active Pending
- 2023-10-26 AU AU2023254980A patent/AU2023254980A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52488B1 (fr) | Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation | |
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| JOP20220062A1 (ar) | مركبات rip1 تثبيطية وطرق عملها واستخدامها | |
| MA50804B1 (fr) | Nouveaux antagonistes des récepteurs de bradykinine b2 | |
| FR3057773B1 (fr) | Nouvelles compositions antivirales pour le traitement des infections liees aux coronavirus | |
| MA43131B1 (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
| MA44037B1 (fr) | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci | |
| MA45811A (fr) | Méthodes et compositions de traitement de maladie. | |
| WO2020102646A3 (fr) | Inhibiteurs d'arg1 et/ou d'arg2 | |
| MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
| MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
| MA34516B1 (fr) | Imidizopyridazines substituees | |
| MA30906B1 (fr) | Composes et compositions en tant quinhibiteurs des proteines kinases | |
| MA30504B1 (fr) | Compositions pharmaceutiques stabilisees comprenant de la fesoterodine | |
| MA29723B1 (fr) | Composes | |
| MA51431B1 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MX2022002717A (es) | Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos. | |
| MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| CL2023000069A1 (es) | Mezclas fungicidas | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA42769B1 (fr) | Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1 | |
| MA41174B1 (fr) | Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta | |
| FR3097223B1 (fr) | Adduits silylés, polymères silylés et compositions les comprenant | |
| MA32128B1 (fr) | Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artémisinine ou l'un de ses derives pour le traitement du paludisme severe | |
| MA44383B1 (fr) | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer |